A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 59 weeks and may include up to 22 visits.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 1420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Actual Study Start Date: April 1, 2019
Estimated Primary Completion Date: October 19, 2020
Estimated Study Completion Date: November 19, 2020
Arms:
- Experimental: 5 mg Tirzepatide
- Experimental: 10 mg Tirzepatide
- Experimental: 15 mg Tirzepatide
- Active Comparator: Insulin Degludec
| Category | Value |
|---|---|
| Date last updated at source | 2019-07-12 |
| Study type(s) | Interventional |
| Expected enrolment | 1420 |
| Study start date | 2019-04-01 |
| Estimated primary completion date | 2020-10-19 |